Oxaliplatin Concentrate Injection and Panitumumab Intravenous

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Talk to your doctor before using panitumumab together with oxaliplatin. Depending on your condition and the type of tumors you have, using panitumumab in combination with oxaliplatin and other chemotherapy drugs may lead to a worse treatment outcome in terms of disease progression and survival rate than using oxaliplatin alone plus other chemotherapy drugs. Your doctor should perform testing for your specific tumor type before prescribing panitumumab, either alone or with oxaliplatin and other chemotherapy drugs. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

CONTRAINDICATED: Coadministration of panitumumab with oxaliplatin-based chemotherapy may negatively affect the clinical outcome in patients with mutant KRAS metastatic colorectal carcinoma (mCRC) and those with ECOG (Eastern Cooperative Oncology Group) 2 performance status. The mechanism of interaction has not been described. In a phase 3 study consisting of 1183 subjects, of which 656 had wild-type KRAS and 440 had mutant KRAS mCRC, a significant shortening of progression-free survival was observed in subjects with mutant KRAS tumors who received panitumumab in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) as first-line therapy compared to those who received FOLFOX alone (median 7.4 vs 9.2 months). A trend toward shortened overall survival time was also observed in the mutant KRAS mCRC population for panitumumab and FOLFOX relative to FOLFOX alone (median 15.5 vs 19.2 months). In the same study, an exploratory covariate analysis according to ECOG status in subjects with wild-type KRAS mCRC showed that patients with ECOG 2 performance status (n=40) had increased toxicity and significant shortening of progression-free survival (median 4.8 vs 10.8 months) and overall survival time (median 7.0 vs 25.8 months) when given panitumumab plus FOLFOX compared to patients with ECOG 0 or 1 performance status (n=616). Moreover, progression-free survival and overall survival time were shortened in the ECOG 2 patients given panitumumab plus FOLFOX versus FOLFOX alone (median 4.8 vs 7.5 months and 7.0 vs 11.7 months, respectively). In elderly patients, an increased number of serious adverse events were reported for panitumumab in combination with FOLFOX compared to chemotherapy alone (52% vs 37%). The most increased serious adverse event was severe diarrhea.

MANAGEMENT: The use of panitumumab in combination with oxaliplatin-based chemotherapy is considered contraindicated in patients with mutant KRAS mCRC (i.e., KRAS mutations in codon 12 or 13) or in whom KRAS mCRC status is unknown. KRAS mutational status should be determined using a validated test method by an experienced laboratory. For patients with ECOG 2 performance status, assessment of risks versus benefits is recommended prior to initiation of panitumumab in combination with oxaliplatin-based chemotherapy for the treatment of mCRC. A positive benefit-risk balance has not been documented in this population.

Oxaliplatin Concentrate Injection

Generic Name: oxaliplatin

Brand name: Eloxatin

Synonyms: Oxaliplatin

What is Oxaliplatin Concentrate Injection?

Panitumumab Intravenous

Generic Name: panitumumab

Brand name: Vectibix

Synonyms: Panitumumab

What is Panitumumab Intravenous?